Effects of Intravenous Administration of Vancomycin on Peritonitis in a Patient on Peritoneal Dialysis.

In settings where intraperitoneal vancomycin is unavailable or off-label (e.g., Japan), intravenous vancomycin can be a viable treatment option for peritoneal dialysis-associated peritonitis. Due to limited pharmacokinetic data regarding intravenous dosing, pragmatic strategies involving more frequent therapeutic drug monitoring-measuring both serum levels for systemic safety and dialysate levels for intraperitoneal antimicrobial exposure-can help ensure therapeutic efficacy while maintaining patient safety.